abstract |
The present invention relates to a novel compound having the ability to inhibit the 11β-HSD1 enzyme or a pharmaceutically acceptable salt thereof, a method for producing the same, and a pharmaceutical composition containing the same as an active ingredient. Since the compounds according to the invention selectively inhibit the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), diseases caused by excessive activity of 11β-HSD1, such as insulin-independent (type 2) diabetes Insulin resistance, obesity, lipid disorders, metabolic syndrome, and can be effectively used as a therapeutic agent to treat diseases and conditions caused by excessive activity of glucocorticoids. [Selection figure] None |